Comparison of risk factors in the 2 treatment-intensity groups within the retrospective cohort
| . | Patients, % . | ||
|---|---|---|---|
| Characteristic . | Less intensive . | Intensive . | P . |
| Age ≥65 y | 87 | 26 | <.0001 |
| Age ≥75 y | 43 | 5 | <.0001 |
| Augmented HCT-CI score ≥4 | 72 | 52 | <.0001 |
| Mean augmented HCT-CI score | 5.3 | 4.2 | <.0001 |
| 2017 ELN adverse risk group | 46 | 29 | <.0001 |
| AML-CM score ≥7 | 75 | 46 | <.0001 |
| Mean AML-CM score | 9.0 | 6.5 | <.0001 |
| . | Patients, % . | ||
|---|---|---|---|
| Characteristic . | Less intensive . | Intensive . | P . |
| Age ≥65 y | 87 | 26 | <.0001 |
| Age ≥75 y | 43 | 5 | <.0001 |
| Augmented HCT-CI score ≥4 | 72 | 52 | <.0001 |
| Mean augmented HCT-CI score | 5.3 | 4.2 | <.0001 |
| 2017 ELN adverse risk group | 46 | 29 | <.0001 |
| AML-CM score ≥7 | 75 | 46 | <.0001 |
| Mean AML-CM score | 9.0 | 6.5 | <.0001 |
AML-CM cytogenetics combining age, comorbidities, and ELN risk.